Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer

被引：4
作者：
Kogawa, Takahiro
Yonemori, Kan
Naito, Yoichi
Noguchi, Emi
Shimizu, Chikako
Tamura, Kenji
Hosono, Ako
Matsubara, Nobuaki
Sugihara, Masahiro
Ogawa, Hayao
Majima, Shuji
Yu, Channing
Ueno, Suguru
Takano, Toshimi
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS1116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1116
引用
收藏
页数：5
相关论文
共 50 条
[41]   Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer [J].
Shimizu, Toshio ;
Yonesaka, Kimio ;
Hayashi, Hidetoshi ;
Iwasa, Tsutomu ;
Haratani, Koji ;
Yamada, Hironori ;
Ohwada, Shoichi ;
Kamiyama, Emi ;
Nakagawa, Kazuhiko .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) :489-495
[42]   First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors [J].
Gutierrez, Martin E. ;
Tang, Shou-Ching ;
Powderly, John D. ;
Balmanoukian, Ani S. ;
Hoyle, Paul E. ;
Dong, Zhiwan ;
Cheng, Lulu ;
Gong, Xiaohua ;
Janik, John E. ;
Bourayou, Nawel ;
Hamid, Omid .
ONCOLOGIST, 2025, 30 (07)
[43]   A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors [J].
Hamilton, Erika ;
Zhang, Jian ;
Liu, Liming ;
Gao, Jie ;
Shi, Rong ;
Liu, Shengxue ;
Wei, Gu ;
Qiu, Yang ;
Moore, Kathleen .
CANCER RESEARCH, 2023, 83 (08)
[44]   A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid tumors [J].
LoRusso, P. ;
Keedy, V. ;
Yee, L. ;
Oliveira, M. ;
Rizvi, N. ;
Berlin, J. ;
Jin, X. ;
Hettmann, T. ;
Copigneaux, C. ;
Beaupre, D. .
EJC SUPPLEMENTS, 2010, 8 (07) :76-76
[45]   Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE) [J].
Woodward, N. ;
De Boer, R. H. ;
Redfern, A. ;
White, M. ;
Young, J. ;
Truman, M. ;
Beith, J. .
CANCER RESEARCH, 2016, 76
[46]   Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer [J].
Toshio Shimizu ;
Kimio Yonesaka ;
Hidetoshi Hayashi ;
Tsutomu Iwasa ;
Koji Haratani ;
Hironori Yamada ;
Shoichi Ohwada ;
Emi Kamiyama ;
Kazuhiko Nakagawa .
Cancer Chemotherapy and Pharmacology, 2017, 79 :489-495
[47]   BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody- drug conjugate, in patients with locally advanced or metastatic solid tumours: afirst-in-human, open-label, multicentre, phase 1 study [J].
Ma, Yuxiang ;
Huang, Yan ;
Zhao, Yuanyuan ;
Zhao, Shen ;
Xue, Jinhui ;
Yang, Yunpeng ;
Fang, Wenfeng ;
Guo, Ye ;
Han, Yaqian ;
Yang, Kunyu ;
Li, Yongsheng ;
Yang, Jun ;
Fu, Zhenming ;
Chen, Gang ;
Chen, Likun ;
Zhou, Ningning ;
Zhou, Ting ;
Zhang, Yaxiong ;
Zhou, Huaqiang ;
Liu, Qianwen ;
Zhu, Yi ;
Zhu, Hai ;
Xiao, Sa ;
Zhang, Li ;
Zhao, Hongyun .
LANCET ONCOLOGY, 2024, 25 (07) :901-911
[48]   BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study [J].
Song, Erwei ;
Yao, Herui ;
Sun, Meili ;
Zong, Hong ;
Lin, Rongbo ;
Zou, Wen ;
Ding, Muran ;
Yu, Jing ;
Xiao, Sa ;
Wang, Hongwei ;
Zhu, Hai ;
Olivo, Martin ;
Zhu, Yi .
CANCER RESEARCH, 2024, 84 (09)
[49]   Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors. [J].
Moore, Kathleen N. ;
Bendell, Johanna C. ;
Olszanski, Anthony J. ;
Desai, Madhuri ;
Jansen, Mendel ;
Scheyer, Richard David ;
Senaldi, Giorgio ;
LoRusso, Patricia .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[50]   A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer. [J].
Jiang, Zefei ;
Sun, Tao ;
Wang, Xiaojia ;
Liu, Qiang ;
Yan, Min ;
Tong, Zhongsheng ;
Geng, Cuizhi ;
Tang, Jinhai ;
Yin, Yongmei ;
Yu, Guohua ;
Wang, Jingfen ;
Su, Wuyun ;
Wang, Shusen ;
Pan, Yueyin ;
Yang, Hua .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345